We are live on ! Find out more
PHIO icon

Phio Pharmaceuticals
PHIO

3 hedge funds and large institutions have $132K invested in Phio Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.62% less ownership

Funds ownership: 1.79% → 1.17% (-0.62%)

40% less funds holding

Funds holding: 5 → 3 (-2)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

55% less capital inflows, than outflows

Capital inflows: $34.5K | Capital outflows: $76.5K

Holders
3
Holders Change
-2
Holders Change %
-40%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$34.5K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$34.5K
2
UBS Group
UBS Group
Switzerland
-$20K
3
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
-$13K
4
Bank of New York Mellon
Bank of New York Mellon
New York
-$6K
5
Ferris Capital
Ferris Capital
Massachusetts
-$2K

PHIO Hedge Fund Activity: Q3 2017 in Review

3 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q3 2017, worth a combined $132K — down 43% from $230K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of PHIO and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest buyer was Millennium Management, opening a new position worth an estimated $34.5K. The largest seller was Citadel Advisors, exiting entirely with an estimated $34.5K sold.

  • 3 institutional investors held Phio Pharmaceuticals (PHIO) as of Q3 2017, down from 5 in Q2 2017.
  • Funds reported $132K of Phio Pharmaceuticals stock for Q3 2017, down 43% quarter-over-quarter.
  • 1 fund opened new Phio Pharmaceuticals positions in Q3 2017 and 2 closed out, a net change of -1 holder.
  • The largest Phio Pharmaceuticals buyer in Q3 2017 was Millennium Management, an estimated $34.5K added.
  • The largest Phio Pharmaceuticals seller in Q3 2017 was Citadel Advisors, an estimated $34.5K sold.

Based on aggregated 13F filings for Q3 2017.